Expert commentary: A primary care view of the REWIND trial
Kamlesh Khunti discusses what the REWIND findings mean for doctors working with people with type 2 diabetes and high cardiovascular risk in primary care (1:43).
- News story | Dulaglutide cardioprotective in relatively low-risk REWIND population
- Expert commentary | The REWIND trial
- Expert commentary | A nurse educator’s view of the REWIND trial